Galena Biopharma's Abstral serves as model for TIRF REMS program

May 9, 2013

Galena Biopharma presented information on the development of a Transmucosal Immediate Release Fentanyl REMS program. The poster presentation describes the development and implementation of the now fully implemented TIRF REMS program for this important class of drug. Abstral's sublingual TIRF REMS program served as a model for the current shared TIRF REMS.The poster concluded that the TIRF REMS program is an important step toward the FDA Amendments Act goals to reduce misuse, abuse, addiction, overdose, and medication-related errors.